Graves' ophthalmopathy: Epidemiology and natural history

Internal Medicine

Volumn 53, Issue 5, 2014, Pages 353-360

  Hiromatsu, Yuji ^a   Eguchi, Hiroyuki ^a   Tani, Junichi ^a   Kasaoka, Masataka ^a   Teshima, Yasuo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Epidemiology; Ethnicity; Graves' disease; Graves' ophthalmopathy; Prevalence

Indexed keywords

RADIOACTIVE IODINE; THYROTROPIN;

AGING; CLINICAL FEATURE; DISEASE SEVERITY; ENDOCRINE OPHTHALMOPATHY; ENVIRONMENTAL FACTOR; ETHNICITY; EUTHYROIDISM; GRAVES DISEASE; HASHIMOTO DISEASE; HEREDITY; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; MORBIDITY; PREVALENCE; REVIEW; RISK FACTOR; SEX DIFFERENCE; SMOKING; THYROID DISEASE; THYROID FUNCTION; GRAVES OPHTHALMOPATHY; HEALTH; INCIDENCE;

GLOBAL HEALTH; GRAVES OPHTHALMOPATHY; HUMANS; INCIDENCE; PREVALENCE; RISK FACTORS;

EID: 84895108634     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.53.1518     Document Type: Review

References (89)

1. Bartalena L, Tanda ML. Clinical practice. Graves' ophthalmopathy. N Engl J Med 360: 994-1001, 2009.
2. Bahn RS. Graves' ophthalmopathy. N Engl J Med 362: 726-738, 2010.
3. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 21: 168-199, 2000.
4. Lazarus JH. Epidemiology of Graves' orbitopathy (GO) and relationship with thyroid disease. Best Pract Res Clin Endocrinol Metab 26: 273-279, 2012.
5. Khalilzadeh O, Noshad S, Rashidi A, Amirzargar A. Graves' ophthalmopathy: a review of immunogenetics. Curr Genomics 12: 564-575, 2011.
6. Cawood TJ, Moriarty P, O'Farrelly C, O'Shea D. Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link. J Clin Endocrinol Metab 92: 59-64, 2007.
7. Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 92: 477-588, 1994.
8. Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 7: 481-493, 1997.
9. Berglund J, Ericsson UB, Hallengren B. Increased incidence of thyrotoxicosis in Malmö during the years 1988-1990 as compared to the years 1970-1974. J Intern Med 239: 57-62, 1996.
10. Flynn RW, MacDonald TM, Morris AD, Jung RT, Leese GP. The thyroid epidemiology, audit, and research study: thyroid dysfunction in the general population. J Clin Endocrinol Metab 89: 3879-3884, 2004.
11. Leese GP, Flynn RV, Jung RT, Macdonald TM, Murphy MJ, Morris AD. Increasing prevalence and incidence of thyroid disease in Tayside, Scotland: the Thyroid Epidemiology Audit and Research Study (TEARS). Clin Endocrinol (Oxf) 68: 311-316, 2008.
12. Abraham-Nordling M, Törring O, Lantz M, et al. Incidence of hyperthyroidism in Stockholm, Sweden, 2003-2005. Eur J Endocrinol 158: 823-827, 2008.
13. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 87: 489-499, 2002.
14. Holm IA, Manson JE, Michels KB, Alexander EK, Willett WC, Utiger RD. Smoking and other lifestyle factors and the risk of Graves' hyperthyroidism. Arch Intern Med 165: 1606-1611, 2005.
15. Abraham R, Srinivasa Murugan, Pukazhvanthen P, Sen SK. Thyroid disorders in women of Puducherry. Indian J Clin Biochem 24: 52-59, 2009.
16. Lim SL, Lim AK, Mumtaz M, Hussein E, Wan Bebakar WM, Khir AS. Prevalence, risk factors, and clinical features of thyroidassociated ophthalmopathy in multiethnic Malaysian patients with Graves' disease. Thyroid 18: 1297-1301, 2008.
17. Torizuka K, Imura H, Konishi J, et al. A statistical survey on Japanese patients with malignant exophthalmos. Folia Endocrinol Jap 57: 1-16, 1981 (in Japanese, Abstract in English).
18. Wiersinga WM, Smit T, van der Gaag R, Koornneef L. Temporal relationship between onset of Graves' ophthalmopathy and onset of thyroidal Graves' disease. J Endocrinol Invest 11: 615-619, 1988.
19. Marcocci C, Bartalena L, Bogazzi F, Panicucci M, Pinchera A. Studies on the occurrence of ophthalmopathy in Graves' disease. Acta Endocrinol (Copenh) 120: 473-478, 1989.
20. Bartley GB, Fatourechi V, Kadrmas EF, et al. Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 121: 284-290, 1996.
21. Gorman CA. Temporal relationship between onset of Graves' ophthalmopathy and diagnosis of thyrotoxicosis. Mayo Clin Proc 58: 515-519, 1983.
22. Kendler DL, Lippa J, Rootman J. The initial clinical characteristics of Graves' orbitopathy vary with age and sex. Arch Ophthalmol 111: 197-201, 1993.
23. Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 14: 747-793, 1993.
24. Kriss JP, Pleshakov V, Rosenblum AL, Holderness M, Sharp G, Utiger R. Studies on the pathogenesis of the ophthalmopathy of Graves' disease. J Clin Endocrinol Metab 27: 582-593, 1967.
25. Solomon DH, Chopra IJ, Chopra U, Smith FJ. Identification of subgroups of euthyroid Graves's ophthalmopathy. N Engl J Med 296: 181-186, 1977.
26. Marcocci C, Bruno-Bossio G, Manetti L, et al. The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study. Clin Endocrinol (Oxf) 51: 503-508, 1999.
27. Kim JM, LaBree L, Levin L, Feldon SE. The relation of Graves' ophthalmopathy to circulating thyroid hormone status. Br J Ophthalmol 88: 72-74, 2004.
28. Perros P, Crombie AL, Matthews JN, Kendall-Taylor P. Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin Endocrinol (Oxf) 38: 367-372, 1993.
29. Kozaki A, Inoue R, Komoto N, et al. Proptosis in dysthyroid ophthalmopathy: a case series of 10,931 Japanese cases. Optom Vis Sci 87: 200-204, 2010.
30. Forbes G, Gorman CA, Brennan MD, Gehring DG, Ilstrup DM, Earnest F 4th. Ophthalmopathy of Graves' disease: computerized volume measurements of the orbital fat and muscle. AJNR Am J Neuroradiol 7: 651-656, 1986.
31. Abraham-Nordling M, Byström K, Törring O, et al. Incidence of hyperthyroidism in Sweden. Eur J Endocrinol 165: 899-905, 2011.
32. Manji N, Carr-Smith JD, Boelaert K, et al. Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype. J Clin Endocrinol Metab 91: 4873-4880, 2006.
33. Bartalena L, Wiersinga WM, Pinchera A. Graves' ophthalmopathy: state of the art and perspectives. J Endocrinol Invest 27: 295-301, 2004.
34. Krassas GE. Childhood Graves' orbitopathy. In: Graves' Orbitopathy: A Multidisciplinary Approach-Questions and Answers. 2nd ed. Wiersinga WM, Kahaly GJ, Eds. Karger, Basel, 2010: 239-247.
35. Young LA. Dysthyroid ophthalmopathy in children. J Pediatr Ophthalmol Strabismus 16: 105-107, 1979.
36. Uretsky SH, Kennerdell JS, Gutai JP. Graves' ophthalmopathy in childhood and adolescence. Arch Ophthalmol 98: 1963-1964, 1980.
37. Grüters A. Ocular manifestations in children and adolescents with thyrotoxicosis. Exp Clin Endocrinol Diabetes 107 (Suppl 5): S172-S174, 1999.
38. Chan W, Wong GW, Fan DS, Cheng AC, Lam DS, Ng JS. Ophthalmopathy in childhood Graves' disease. Br J Ophthalmol 86: 740-742, 2002.
39. Durairaj VD, Bartley GB, Garrity JA. Clinical features and treatment of Graves' ophthalmopathy in pediatric patients. Ophthal Plast Reconstr Surg 22: 7-12, 2006.
40. Blake CR, Lai WW, Edward DP. Racial and ethnic differences in ocular anatomy. Int Ophthalmol Clin 43: 9-25, 2003.
41. Chng CL, Seah LL, Khoo DHC. Ethnic differences in the clinical presentation of Graves' ophthalmopathy. Best Pract Res Clin Endocrinol Metab 262: 249-258, 2012
42. de Juan E Jr, Hurley DP, Sapira JD. Racial differences in normal values of proptosis. Arch Intern Med 140: 1230-1231, 1980.
43. Tsai CC, Kau HC, Kao SC, Hsu WM. Exophthalmos of patients with Graves' disease in Chinese of Taiwan. Eye (Lond) 20: 569-573, 2006.
44. Amino N, Yuasa T, Yabu Y, Miyai K, Kumahara Y. Exophthalmos in autoimmune thyroid disease. J Clin Endocrinol Metab 51: 1232-1234, 1980.
45. Kim IT, Choi JB. Normal range of exophthalmos values on orbit computerized tomography in Koreans. Ophthalmologica 215: 156-162, 2001.
46. Rootman J. Aspects of current management of thyroid orbitopathy in Asians. Asia Pacific J Ophthalmol 10: 2-6, 1998.
47. Daumerie C. Epidemiology in Graves' orbitopathy. In: Graves' Orbitopathy: A Multidisciplinary Approach-Questions and Answers. 2nd ed. Wiersinga WM, Kahaly GJ, Eds. Karger, Basel, 2010: 33-39.
48. Hiromatsu Y, Kojima K, Ishisaka N, et al. Role of magnetic resonance imaging in thyroid-associated ophthalmopathy: its predictive value for therapeutic outcome of immunosuppressive therapy. Thyroid 2: 299-305, 1992.
49. Kirsch E, Hammer B, von Arx G. Graves' orbitopathy: current imaging procedures. Swiss Med Wkly 139: 618-623, 2009.
50. Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid 18: 333-346, 2008.
51. Tachibana S, Murakami T, Noguchi H, et al. Orbital magnetic resonance imaging combined with clinical activity score can improve the sensitivity of detection of disease activity and prediction of response to immunosuppressive therapy for Graves' ophthalmopathy. Endocr J 57: 853-861, 2010.
52. Classification of eye changes of Graves' disease. Thyroid 2: 235-236, 1992.
53. Dckinson AJ. Clinical manifestations. In: Graves' Orbitopathy: A Multidisciplinary Approach-Questions and Answers. 2nd ed. Wiersinga WM, Kahaly GJ, Eds. Karger, Basel, 2010: 1-25.
54. Villadolid MC, Yokoyama N, Izumi M, et al. Untreated Graves' disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance. J Clin Endocrinol Metab 80: 2830-2833, 1995.
55. Enzmann DR, Donaldson SS, Kriss JP. Appearance of Graves' disease on orbital computed tomography. J Comput Assist Tomogr 3: 815-819, 1997.
56. Gupta A, Sadeghi PB, Akpek EK. Occult thyroid eye disease in patients presenting with dry eye symptoms. Am J Ophthalmol 147: 919-923, 2009.
57. Tellez M, Cooper J, Edmonds C. Graves' ophthalmopathy in relation to cigarette smoking and ethnic origin. Clin Endocrinol (Oxf) 36: 291-294, 1992.
58. Krassas GE, Segni M, Wiersinga WM. Childhood Graves' ophthalmopathy: results of a European questionnaire study. Eur J Endocrinol 153: 515-521, 2005.
59. Laurberg P, Berman DC, Bülow Pedersen I, Andersen S, Carlé A. Incidence and clinical presentation of moderate to severe Graves' orbitopathy in a Danish population before and after iodine fortification of salt. J Clin Endocrinol Metab 97: 2325-2332, 2012.
60. Perros P, Kendall-Taylor P. Natural history of thyroid eye disease. Thyroid 8: 423-425, 1998.
61. Weetman AP, Wiersinga WM. Current management of thyroidassociated ophthalmopathy in Europe. Results of an international survey. Clin Endocrinol (Oxf) 49: 21-28, 1998.
62. Rundle FF, Wilson CW. Development and course of exophthalmos and ophthalmoplegia in Graves' disease with special reference to the effect of thyroidectomy. Clin Sci 5: 177-194, 1945.
63. Rundle FF. Management of exophthalmos and related ocular changes in Graves' disease. Metabolism 6: 36-48, 1957.
64. Wiersinga WM. Advances in medical therapy of thyroid-associated ophthalmopathy. Orbit 15: 177-186, 1996.
65. Streeten DH, Anderson GH Jr, Reed GF, Woo P. Prevalence, natural history and surgical treatment of exophthalmos. Clin Endocrinol (Oxf) 27: 125-133, 1987.
66. Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) 42: 45-50, 1995.
67. Noth D, Gebauer M, Müller B, Bürgi U, Diem P. Graves' ophthalmopathy: natural history and treatment outcomes. Swiss Med Wkly 131: 603-639, 2001.
68. Tanda ML, Piantanida E, Liparulo L, et al. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center. J Clin Endocrinol Metab 98: 1443-1449, 2013.
69. Tallstedt L, Lundell G, Tørring O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 326: 1733-1738, 1992.
70. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 338: 73-78, 1998.
71. Tallstedt L, Lundell G, Blomgren H, Bring J. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol 130: 494-497, 1994.
72. Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy. J Clin Endocrinol Metab 90: 5321-5323, 2005.
73. Träisk F, Tallstedt L, Abraham-Nordling M, et al. Thyroidassociated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 94: 3700-3707, 2009.
74. Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 17: 456-520, 2011.
75. Selva D, Chen C, King G. Late reactivation of thyroid orbitopathy. Clin Experiment Ophthalmol 32: 46-50, 2004.
76. Eckstein AK, Plicht M, Lax H, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91: 3464-3470, 2006.
77. Kamizono S, Hiromatsu Y, Seki N, et al. A polymorphism of the 5' flanking region of tumour necrosis factor alpha gene is associated with thyroid-associated ophthalmopathy in Japanese. Clin Endocrinol (Oxf) 52: 759-764, 2000.
78. Vestergaard P. Smoking and thyroid disorders: a meta-analysis. Eur J Endocrinol 146: 153-161, 2002.
79. Bartalena L, Martino E, Marcocci C, et al. More on smoking habits and Graves' ophthalmopathy. J Endocrinol Invest 12: 733-737, 1989.
80. Hegediüs L, Brix TH, Vestergaard P. Relationship between cigarette smoking and Graves' ophthalmopathy. J Endocrinol Invest 27: 265-271, 2004.
81. Khoo DH, Ho SC, Seah LL, et al. The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy. Thyroid 9: 1175-1180, 1999.
82. Noh JY, Hamada N, Inoue Y, Abe Y, Ito K, Ito K. Thyroidstimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease. Thyroid 10: 809-813, 2000.
83. Goh SY, Ho SC, Seah LL, Fong KS, Khoo DH. Thyroid autoantibody profiles in ophthalmic dominant and thyroid dominant Graves' disease differ and suggest ophthalmopathy is a multiantigenic disease. Clin Endocrinol (Oxf) 60: 600-607, 2004.
84. Lytton SD, Ponto KA, Kanitz M, Matheis N, Kohn LD, Kahaly GJ. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy. J Clin Endocrinol Metab 95: 2123-2131, 2010.
85. Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf) 52: 267-271, 2000.
86. Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab 90: 5234-5240, 2005.
87. Eckstein AK, Plicht M, Lax H, et al. Clinical results of antiinflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies. Clin Endocrinol (Oxf) 61: 612-618, 2004.
88. Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol (Oxf) 69: 943-950, 2008.
89. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Tørring O. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 158: 69-75, 2008.